Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC By Ogkologos - June 6, 2025 659 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from integrated analyses of sotorasib clinical efficacy biomarkers in the CodeBreaK 100 and CodeBreaK 200 studies Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR FDA Approvals Expand Initial Treatment Options for Multiple Myeloma January 7, 2025 The Right to be Forgotten: ESMO Calls on EU Countries to... October 18, 2023 FDA Approves Lazertinib with Amivantamab-vmjw for Locally Advanced or Metastatic NSCLC... September 9, 2024 A new approach to cancer immunotherapy March 18, 2022 Load more HOT NEWS For HPV-Positive Women, Test Can Guide Cervical Cancer Screening Follow-Up FDA Approves Sacituzumab Govitecan-hziy for HR-positive Advanced Breast Cancer Researchers Find New, Effective Tools to Determine Breast Cancer Risk Using... 如何捐赠头发来帮助癌症患者
